Business News • PR NewsWire • Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone...

View More : http://www.prnewswire.com/news-releases/prolia-denosumab-phase-2-extension-study-showed-continued-increase-in-bone-miner...

Releted News by prnewswire

Sanford Guide Introduces New Hepatitis Guide

Guia Sanford apresenta novo guia sobre hepatite

Sanford Guide gibt neues Hepatitis-Handbuch heraus

Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment

NEW Texas Giant Named Best New Ride of 2011

Hollywood Nail Creations tm Reveals Its Best Tool For Creating Celebrity Style Nails!